News
NETRF Awards Eleven Research Grants to Study Neuroendocrine Cancer
U.S. & International Scientists to focus on drug therapies, radiopharmaceuticals, and progression of NETs [BOSTON, MA, January 17, 2024–] The Neuroendocrine Tumor Research Foundation (NETRF)
Growth-factor Dependence in Lung Neuroendocrine Tumors
Lung neuroendocrine tumors (NETs) are graded as typical or atypical carcinoids based on how quickly the tumor cells divide. They exhibit diverse clinical behaviors and
Exploring Midgut NETs Through the Lens of the Microbiome
Midgut neuroendocrine tumors (NETs), such as small intestinal NETs, originate in the neuroendocrine cells of the midgut, a part of the digestive system, and have
Crinetics Announces Positive Results From Phase II Study of Paltusotine
The initial findings of a Phase 2 study have shown that the investigational drug paltusotine may significantly reduce both the frequency and intensity of bowel
Celebrating Milestones in Neuroendocrine Tumor Research
As we reflect on the past year, the Neuroendocrine Tumor Research Foundation (NETRF) takes immense pride in the strides we have made towards understanding and
NETRF Research Symposium Sparks Research Excitement in Boston!
NETRF’s 2023 Margie and Robert E Petersen Neuroendocrine Tumor Research Symposium brought together a hundred of the world’s foremost neuroendocrine cancer scientists in Boston. The
Understanding the Role of ANGPT2 in Pancreatic Neuroendocrine Tumors
Almost half of patients diagnosed with pancreatic neuroendocrine tumors (PanNETs) have tumors that have spread to their liver, which correlates with poorer outcomes. Given this,
Research Milestone in NETRF-funded Science: CAR T Therapy Clinical Trial Announced for NETs
The Neuroendocrine Tumor Research Foundation celebrates a significant milestone in cancer therapy: a first-in-human CAR T cell therapy clinical trial for neuroendocrine tumors (NETs) will
NETTER II Trial Reaches Primary Endpoint
Positive results from the Phase III NETTER-2 trial were reported in September. The NETTER-2 trial is a randomized, multi-center trial evaluating whether Lutathera® plus long-acting
Merci Montreal and NANETS
CEO Elyse Gellerman and Director of Patient Education Jessica Thomas joined 400 NET specialists, researchers, and patient advocates in Montreal for the NANETS 2023 Symposium.